-
Oct 21, 2024 | 
jamanetwork.com | Kevin A. Schulman |Barak D. Richman
Addressing Surprise Medical Bills and Out-of-Network Prices It is no secret that the US has a complicated financial backbone for the health care system. Private health plans set different prices with different physicians and hospitals (collectively, providers) for so-called in-network care.
-
Oct 15, 2024 | 
nature.com | Aditya Narayan |Kevin A. Schulman
India’s evolving digital health strategy leverages innovative technologies to enhance access to healthcare services. This paper explores the key components of India’s digital health transformation, including the Ayushman Bharat Digital Mission (ABDM) and India’s integration of biometric identification and digital infrastructure to improve healthcare delivery.
-
Oct 9, 2024 | 
jacc.org | Sneha Jain |Ashish Sarraju |Nigam H. Shah |Kevin A. Schulman
References1. "Estimated costs of pivotal trials for novel therapeutic agents approved by the US Food and Drug Administration, 2015-2016". JAMA Intern Med . 2018;178:11: 1451-1457. 2. "Participation of women in clinical trials supporting FDA approval of cardiovascular drugs". J Am Coll Cardiol . 2018;71:18: 1960-1969. 3. "Artificial intelligence in cardiovascular clinical trials". J Am Coll Cardiol . 2024;84:2051-2062. 4.
-
Sep 17, 2024 | 
onlinelibrary.wiley.com | Kevin A. Schulman |Aaron S. Kesselheim |William B. Feldman |Iselin Dahlen Syversen
Policy Points Health care systems around the world rely on a range of methods to ensure the affordability of prescription drugs, including negotiating prices soon after drug approval and relying on formal clinical assessments that compare newly approved therapies with existing alternatives. The negotiation framework established under the Inflation Reduction Act is far more limited than other frameworks explored in this study.
-
Dec 1, 2023 | 
healthaffairs.org | Kevin A. Schulman
This year, the pharmaceutical market continues to be in the news. The Senate has taken up legislation placing new requirements on pharmacy benefit managers (PBMs), while the summer saw yet another drug shortage crisis, this time with generic cancer therapies, including Cisplatin. In the frantic search for understanding why these shortages have occurred, many policy makers asked questions about the role of hospital group purchasing organizations (GPOs) in the generic drug market.
-
Aug 9, 2023 | 
gsb.stanford.edu | Kevin A. Schulman |Noel Ayoub |Frank Lin
2023 | Case No. SM367 | Length 20 pgs. New digital technologies and advances in hearing aids could help people hear more clearly, but hearing aids could cost thousands of dollars—and Medicare didn’t cover the cost of the devices. This case study discusses the disruption to the U.S. hearing aid market in the United after the Biden administration created a new regulatory pathway for the sale and service of over-the-counter hearing aids, without a prescription.
-
May 31, 2023 | 
competitionpolicyinternational.com | Barak D. Richman |Kevin A. Schulman
Even though the U.S. healthcare system exhibits higher administrative costs than any other OECD nation, they have not received substantial attention from policymakers despite their enormous cost and impact on the market. We argue that competition policy could meaningfully reduce these administrative costs.
-
May 4, 2023 | 
jamanetwork.com | Barak D. Richman |Kevin A. Schulman
In November 2021, the Centers for Medicare & Medicaid Services (CMS) announced that the monthly Medicare Part B premium would rise from $148.50 in 2021 to $170.10 in 2022, a 14.5% increase.1 This was the largest increase in dollar terms since the start of the program and the third largest percentage rise since 2005.2 CMS explained that the increase was due in large part to the anticipated costs associated with aducanumab, a new Alzheimer disease drug manufactured by Biogen with an initial...
-
May 2, 2023 | 
jamanetwork.com | Barak D. Richman |Kevin A. Schulman
Challenges to Forming Physician Unions—Reply In Reply We have been startled by the number of physicians who have contacted us after the publication of our Editorial,1 and many have relayed sentiments similar to those expressed by Dr Westbrook. The appeal of physician unions is a product of deep professional dissatisfaction with hospital-led medicine and a widespread sense that consolidated health care systems are not designed to serve the best interest of patients.
-
Apr 4, 2023 | 
jamanetwork.com | Barak D. Richman |Kevin A. Schulman
Do Patient Satisfaction Instruments Harm Patients and Physicians?—Reply In Reply In his Letter about our recent Viewpoint,1 Dr Lee shares our concerns over the linkage of financial incentives for individual physicians to patient satisfaction measures such as the use of the Clinician and Group Consumer Assessment of Healthcare Provider and Systems survey (CG-CAHPS) in the Centers for Medicare & Medicaid Services (CMS) Merit-Based Incentive Payment System.
